Compare Stocks → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:CSBRNASDAQ:GMDANASDAQ:LJPCNASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/ACSBRChampions Oncology$4.96+2.1%$10.15$7.19▼$14.68$67.41M0.42,328 shs545 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsOTLKOutlook Therapeutics$7.73-3.4%$8.50$4.00▼$40.60$104.10M0.28495,051 shs222,655 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%+0.00%+0.00%+0.00%CSBRChampions Oncology+1.65%+1.46%-0.90%-19.02%+15.42%GMDAGamida Cell0.00%-3.65%-3.97%-96.22%-99.17%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%OTLKOutlook Therapeutics-3.37%-9.06%-16.52%-6.67%-67.25%The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACSBRChampions Oncology3.4262 of 5 stars3.32.00.04.60.62.50.0GMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AOTLKOutlook Therapeutics2.5074 of 5 stars3.44.00.00.01.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/ACSBRChampions Oncology2.50Moderate Buy$7.5051.21% UpsideGMDAGamida Cell2.75Moderate Buy$4.75∞ UpsideLJPCLa Jolla PharmaceuticalN/AN/AN/AN/AOTLKOutlook Therapeutics2.88Moderate Buy$46.43500.58% UpsideCurrent Analyst RatingsLatest CSBR, LJPC, GMDA, AYLA, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21CSBRChampions Oncology$53.87M1.25N/AN/A$0.34 per share14.59GMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ACSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)GMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%5/20/2024 (Estimated)LJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/AOTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)Latest CSBR, LJPC, GMDA, AYLA, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q3 2024CSBRChampions OncologyN/A-$0.19-$0.19-$0.19N/A$12.02 million2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28CSBRChampions OncologyN/A0.600.60GMDAGamida Cell213.142.162.09LJPCLa Jolla PharmaceuticalN/A4.023.52OTLKOutlook TherapeuticsN/A0.440.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%CSBRChampions Oncology41.30%GMDAGamida Cell50.34%LJPCLa Jolla Pharmaceutical97.06%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%CSBRChampions Oncology45.69%GMDAGamida Cell3.40%LJPCLa Jolla Pharmaceutical36.30%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableCSBRChampions Oncology14313.59 million7.38 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableCSBR, LJPC, GMDA, AYLA, and OTLK HeadlinesSourceHeadlineOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcastfinance.yahoo.com - May 9 at 9:19 AMOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcastglobenewswire.com - May 9 at 8:45 AMOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Moderate Buy" from Brokeragesamericanbankingnews.com - May 8 at 4:36 AMGlobal $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging Marketsfinance.yahoo.com - May 3 at 3:15 AMHow to fix Microsoft Outlookmsn.com - May 3 at 3:15 AMOutlook Therapeutics® to Present at the Retina World Congress 2024globenewswire.com - May 2 at 9:05 AMEconomic Outlook Conference to be held Monday on CWU campuscwu.edu - May 1 at 8:40 PMCEOs and Investors Navigate Shifting Economic Terrain: Outlook Revealed in EY CEO Pulse Surveynews.europawire.eu - May 1 at 3:40 PMOutlook News Wrap, May 1: 100 Schools In Delhi Get Bomb Threat, Heatwave Alert Issued Amid 47 Deg Temperature, Split In Godrej & Moreoutlookindia.com - May 1 at 9:56 AMQ1 2024 CA Auto Outlook: Tesla registrations drop; Sales slip 7.8% YTDivpressonline.com - April 30 at 2:18 PMNatural Gas News: Freeport LNG Resumption Brightens Outlookfxempire.com - April 29 at 1:15 PMOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcaseglobenewswire.com - April 29 at 9:00 AMThese 5 programs are way better than Microsoft Outlookmsn.com - April 29 at 8:15 AMHCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 Outlookusnews.com - April 29 at 8:15 AMBest's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation Councilfinance.yahoo.com - April 29 at 1:28 AMBulgaria's Eurozone Aspirations: Fitch Ratings Affirms Positive Outlooknovinite.com - April 27 at 7:18 AMOutlook Magazine's Reporters Guarantee: Editor's Exclusiveoutlookindia.com - April 27 at 2:18 AMOutlook man accused of dragging girlfriend with his caryakimaherald.com - April 27 at 2:18 AMGlobal Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036finance.yahoo.com - April 26 at 4:17 PMHow to Use Copilot in Outlookmsn.com - April 26 at 4:17 PMOutlook's Next Issue: Inside The Election Cauldronoutlookindia.com - April 26 at 4:17 PMMedia advisory - OECD Economic Outlook 2024oecd.org - April 26 at 6:16 AMBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positivefinance.yahoo.com - April 22 at 1:21 PMUSD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlookfxempire.com - April 22 at 1:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Champions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.